Načítá se...
RhIG for the treatment of immune thrombocytopenia: consensus and controversy
Anti-D immune globulin (RhIG) is a front-line option in North America for the treatment of immune thrombocytopenia (ITP) in children and adults. Recently, addition of a Food and Drug Administration-mandated black box warning highlighted the risks of intravascular hemolysis, renal failure, and dissem...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3427798/ https://ncbi.nlm.nih.gov/pubmed/21981825 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1537-2995.2011.03384.x |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|